

# Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies

*- Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities -*

HANGZHOU, China, and ROCKVILLE, Md., March 16, 2022 – Innoforce, a global development and biomanufacturing company focused on Advanced Therapy Medicinal Products (“ATMPs”), and [Hibiscus BioVentures](#), a firm committed to building patient-focused companies around transformative technologies, today announced they have formed a strategic partnership to leverage the combined resources of both organizations to advance new ATMPs and biologic medicines in order to accelerate development of [Hibiscus BioTechnology](#) Studio Companies’ product pipeline.

“This strategic partnership with Innoforce underscores our commitment to the growing pipeline of Hibiscus Studio Companies, enhancing our operational capabilities and facilitating the development and commercialization of innovative medicines,” said Chris Jeffers, CEO of Hibiscus BioTechnology.

“We are excited to partner with Hibiscus, which brings a highly experienced team and unique model to develop new technologies that address important unmet medical needs,” said Yuling Li Ph.D. Co-Founder and CEO of Innoforce. “The partnership will leverage our drug

development experience with Hibiscus' pipeline initiatives in alignment with Innoforce's mission to enable global development of novel, advanced biotherapeutics."

### **About Hibiscus BioVentures**

Hibiscus BioVentures is committed to advancing patient care by supporting the development of commercially viable therapies – building patient-focused companies around transformative technologies. Hibiscus has two operating subsidiaries Hibiscus BioTechnology, and Hibiscus Capital Management. Learn more about Hibiscus here: <https://hibiscusbio.com/>

### **About Innoforce**

Innoforce is a partnership-focused biopharmaceutical company established to enable and accelerate the innovation of breakthrough ATMPs and Biologics. The company has world-class biopharmaceutical manufacturing and development capabilities to serve global markets at its campus in Hangzhou, China, and offices in Rockville, Maryland. Innoforce offers end-to-end contract development and manufacturing service (CDMO), including GMP manufacturing of plasmid DNA, RNA, viral vector, and cell products. In addition, through a joint venture with a leading international supplier of life sciences products & services, the company provides CDMO services for antibody and protein drugs. Innoforce's enabling capabilities for incubating and developing cell, gene, and advanced biological therapies can support partners and portfolio companies to rapidly and efficiently bring cutting-edge treatments that impact patients' lives worldwide. More information is available at <https://www.innoforcepharma.com/>

**Media Contact:**

**Shani Lewis**

LaVoieHealthScience

Email: [slewis@lavoiehealthscience.com](mailto:slewis@lavoiehealthscience.com)

Phone: 609-516-5761

## 健新原力和 Hibiscus BioVentures 宣布建立战略伙伴关系,赋能先进疗法的开发

- 此项合作使 Hibiscus BioTechnology Studio 生物技术公司从健新原力获得先进治疗药物开发的能力 -

中国杭州和美国马里兰州 ROCKVILLE,2022 年 3 月 15 日--健新原力,一家专注于先进治疗药物(“Advanced Therapy Medicinal Products ATMPs”)的全球开发和生物制造公司,携手**美国** Hibiscus BioVentures,围绕变革性技术,致力于建立聚焦患者的不同公司,今天宣布建立战略伙伴关系。双方将汇聚各自丰富的资源,推进新的 ATMPs 和生物药物,以加速开发 Hibiscus BioTechnology Studio Companies 生物技术工作室公司的产品管线。

Hibiscus BioTechnology 公司首席执行官 Chris Jeffers 表示,“与健新原力的这一战略伙伴关系强调了我们对 Hibiscus Studio 公司的管线不断增长的承诺,增强我们的运营能力,以及促进创新药物的开发和商业化。”

“我们很高兴与 Hibiscus 的合作,他们带来了经验丰富的资深团队,以独特的模式去开发新兴技术,不断地解决病人的医疗需求。”健新原力联合创始人和 CEO 李玉玲博士说,

“此项合作将我们健新原力的药物开发经验与 Hibiscus 的产品管线强有力的结合起来,赋能全球新兴和先进生物疗法开发的推进。”

### 关于 Hibiscus BioVentures

Hibiscus BioVentures 致力于通过支持可商业化疗法的开发,推进对患者的服务,建立以病人为中心、围绕多种变革性技术的各类公司。Hibiscus 拥有两个运营子公司,Hibiscus BioTechnology 和 Hibiscus Capital Management。了解更多关于 Hibiscus 的信息请见:<https://hibiscusbio.com/>

### 关于健新原力

健新原力是一家专注于创新和伙伴合作的生物制药公司,旨在促进和加速突破先进治疗药物(ATMPs)创新的公司。公司拥有世界一流的生物制药生产和开发能力,将使用位于中国杭州的工厂和美国马里兰州 Rockville 的办事处服务全球市场。健新原力提供端到端的合同开发与制造服务(CDMO),其中包括质粒 DNA、RNA、病毒载体和细胞治疗产品的 GMP 商业化生产。此外,健新原力还通过与一家领先的国际生命科学产品与服务的供应商成立的合资企业,提供抗体和蛋白质药物 CDMO 服务。公司还拥有在孵化和开发细胞治疗、基因治疗等先进生物疗法方面的能力,能够支持合作伙伴和投资组合公司更高效地推出影响全球患者生活的尖端疗法。

更多信息请见 <https://www.innoforcepharma.com/>

**媒体联系人:**

**Shani Lewis**

LaVoieHealthScience

电子邮件:slewis@lavoiehealthscience.com

电话:+1-609-516-5761